Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMOXICILLIN AND CLAVULANATE POTASSIUM vs AMOXIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
Lower respiratory tract infections,Acute bacterial sinusitis,Otitis media,Urinary tract infections,Skin and skin structure infections,Bone and joint infections,Intra-abdominal infections,Dental infections
Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis/tonsillitis) due to susceptible streptococci, pneumococci, and H. influenzae,Lower respiratory tract infections (e.g., pneumonia, bronchitis) due to susceptible streptococci, pneumococci, and H. influenzae,Genitourinary tract infections (e.g., uncomplicated gonorrhea, cystitis) due to susceptible E. coli, P. mirabilis, and enterococci,Skin and skin structure infections due to susceptible streptococci, staphylococci, and E. coli,Helicobacter pylori eradication (as part of combination therapy),Lyme disease (early localized or early disseminated),Prophylaxis of infective endocarditis (dental procedures) in patients with certain cardiac conditions
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
Amoxicillin undergoes partial hepatic metabolism via hydrolysis. Clavulanate is extensively metabolized in the liver, primarily by hydrolysis and conjugation.
Amoxicillin is primarily metabolized through hydrolysis of the beta-lactam ring to inactive penicilloic acid, accounting for 60-70% of the dose; about 10% is metabolized via hepatic pathways to amoxicilloic acid; renal excretion as unchanged drug is 60-80% via tubular secretion and glomerular filtration.
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in Cr Cl <30 m L/min.
Amoxicillin: ~20% (mainly albumin); Clavulanate: ~25% (albumin).
17-20%, primarily to albumin.
Amoxicillin: ~0.3-0.4 L/kg; Clavulanate: ~0.3 L/kg. Distributes into tissues, not CSF unless inflamed.
0.3-0.4 L/kg; indicates distribution into total body water.
Oral: ~80-90% for amoxicillin; ~60-75% for clavulanate. Enhanced with food.
Oral: 75-90% (variable with food, decreased absorption); IM: near 100%.
For Cr Cl 10-30 m L/min: 250-500 mg amoxicillin component every 12 hours. For Cr Cl <10 m L/min: 250-500 mg amoxicillin component every 24 hours. Hemodialysis: 250-500 mg every 24 hours, give additional dose during and after dialysis.
GFR 10-30 m L/min: 250-500 mg every 12 hours; GFR <10 m L/min: 250-500 mg every 24 hours; hemodialysis: 250-500 mg every 24 hours with an additional dose after dialysis.
No specific dose adjustment recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh C); consider alternative therapy or reduced dosing, but no formal guidelines.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B); caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
For children >3 months: 25-45 mg/kg/day of amoxicillin component divided every 12 hours (based on 200 mg/28.5 mg per 5 m L suspension) or 20-40 mg/kg/day divided every 8 hours (based on 125 mg/31.25 mg per 5 m L suspension). For severe infections, up to 90 mg/kg/day of amoxicillin component divided every 12 hours (using 400 mg/57 mg per 5 m L suspension).
Neonates ≤28 days: 25-30 mg/kg/day divided every 12 hours; Infants and children >28 days: 20-40 mg/kg/day divided every 8 hours; for otitis media: 50-90 mg/kg/day divided every 8-12 hours.
Initiate at lower end of dosing range due to increased risk of renal impairment. Monitor renal function and adjust dose based on creatinine clearance as per renal adjustment guidelines.
No specific dose adjustment based solely on age; monitor renal function and adjust dose based on creatinine clearance (Cr Cl) as per renal adjustment guidelines; maintain adequate hydration.
No FDA boxed warning.
None
Hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome) in patients with penicillin allergy,Clostridioides difficile-associated diarrhea,Hepatic toxicity (elevated liver enzymes, hepatitis, cholestatic jaundice) more common in elderly and with prolonged use,Renal impairment requires dose adjustment,Risk of superinfection with prolonged therapy,Skin rash can occur in patients with mononucleosis
Serious hypersensitivity reactions (anaphylaxis) can occur; contraindicated in patients with penicillin allergy,Clostridium difficile-associated diarrhea (CDAD) may occur, ranging from mild diarrhea to fatal colitis,Prolonged use may result in superinfection with resistant organisms,Hepatic dysfunction and cholestatic jaundice (rare),Skin rashes, including morbilliform rash (common in patients with mononucleosis),Decreased efficacy when used with bacteriostatic agents (e.g., tetracyclines, chloramphenicol),Use with caution in patients with renal impairment (Cr Cl <30 m L/min) due to increased risk of seizures with high doses
History of anaphylactic reaction to penicillins or cephalosporins,Previous cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate,Concurrent use with disulfiram or probenecid (relative)
Known hypersensitivity to amoxicillin, penicillins, or any component of the formulation,Mononucleosis (high incidence of morbilliform rash)
May be taken with or without food; food enhances absorption; avoid ingestion with high-dose clavulanate? (no significant interaction); no specific food restrictions; milk-containing products do not interact significantly.
No significant food interactions; absorption is not altered by food. Avoid excessive alcohol as it may increase risk of GI side effects and hepatotoxicity (rare).
Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Use during first trimester is considered safe if clinically indicated. During second and third trimesters, no known fetal risks. However, avoid use near term due to potential for neonatal kernicterus (theoretical risk from high doses, but not confirmed).
Penicillins, including amoxicillin, are generally considered low risk in pregnancy. Animal studies have not shown teratogenic effects. In humans, data from large cohort studies and meta-analyses do not indicate an increased risk of major congenital malformations, preterm birth, or low birth weight. Use is acceptable if clinically indicated across all trimesters.
Amoxicillin and clavulanate are excreted into breast milk in low concentrations. M/P ratio not established. Considered compatible with breastfeeding by AAP; risk of infant sensitization, diarrhea, or thrush. Use with caution in infants with history of penicillin allergy.
Amoxicillin is excreted into breast milk in small amounts, with an M/P ratio of approximately 0.02-0.05. The estimated dose to the infant is less than 1% of the maternal weight-adjusted dose. It is generally considered compatible with breastfeeding. However, potential risks include infant sensitization, diarrhea, and rash. Monitor for these effects.
Pharmacokinetic changes in pregnancy (increased renal clearance, expanded plasma volume) may require dose adjustments: total daily dose typically remains same but dosing interval may need to be shortened (e.g., every 6-8 hours instead of every 12 hours) for severe infections; monitor clinical response. No standard recommendation for routine adjustment; base on severity and renal function.
Physiologic changes in pregnancy (e.g., increased renal blood flow, GFR, and volume of distribution) may reduce serum concentrations of amoxicillin. While standard dosing may be effective, some experts recommend using the higher end of the dosing range or more frequent dosing for severe infections. However, no specific dose adjustment is routinely required; clinical response should guide therapy.
Use weight-based dosing for pediatric patients; reconstitute oral suspension with appropriate amount of water; administer at start of meal to reduce GI upset; check renal function before dosing; avoid in patients with mononucleosis due to risk of maculopapular rash; higher doses of clavulanate may cause diarrhea; intravenous infusion over 30-40 minutes; consider penicillin allergy cross-reactivity; not effective against MRSA; requires dose adjustment in Cr Cl <30 m L/min.
Amoxicillin is a first-line agent for acute otitis media, streptococcal pharyngitis, and uncomplicated community-acquired pneumonia. It has a time-dependent killing mechanism; optimal efficacy requires maintaining serum concentrations above the MIC for >40% of the dosing interval. Dose adjustment is necessary for creatinine clearance <30 m L/min. It is compatible with clavulanate for beta-lactamase coverage. Rash during therapy may indicate non-allergic ampicillin rash (especially with viral infections) or true hypersensitivity; assess carefully.
Take this medication exactly as prescribed, usually every 12 hours.,Take with food to reduce stomach upset and improve absorption.,Complete the full course even if you feel better.,Shake the oral suspension well before each use.,Store oral suspension in refrigerator, discard after 10 days.,Report severe diarrhea, rash, or signs of allergy immediately.,May cause diarrhea; do not treat without consulting doctor.,Inform your doctor if you are pregnant, breastfeeding, or have liver disease.
Take exactly as prescribed; complete the full course even if you feel better.,May be taken with or without food; avoid large meals if GI upset occurs.,Report any rash, especially if accompanied by hives or difficulty breathing.,Do not use leftover antibiotics; discard after completing course.,Use additional contraception if on oral contraceptives (may reduce efficacy).,For suspension: shake well, measure dose with provided device, refrigerate and discard after 14 days.
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMOXICILLIN AND CLAVULANATE POTASSIUM vs AMOXIL, answered by our medical review team.
AMOXICILLIN AND CLAVULANATE POTASSIUM is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.. AMOXIL is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMOXICILLIN AND CLAVULANATE POTASSIUM and AMOXIL depend on the specific clinical indication. These are both Penicillin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMOXICILLIN AND CLAVULANATE POTASSIUM is: 500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.. The standard adult dose of AMOXIL is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMOXICILLIN AND CLAVULANATE POTASSIUM and AMOXIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMOXICILLIN AND CLAVULANATE POTASSIUM is classified as Category A/B. Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Us. AMOXIL is classified as Category C. Penicillins, including amoxicillin, are generally considered low risk in pregnancy. Animal studies have not shown teratogenic effects. In humans, data from large cohort studies and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.